Company news
Silo Pharma, Inc. news in 2024
Silo Pharma, Inc.'s news releases, calls and decks from 2024, newest first.
Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia
December 17, 2024
Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management
November 28, 2024
Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders
November 17, 2024
Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant
October 30, 2024
Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD
September 9, 2024
Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic
August 13, 2024
Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide
August 6, 2024
Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
July 18, 2024
Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15
July 17, 2024
Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic
July 15, 2024
Silo Pharma Announces Exclusive, Global License for Lead Candidate SPC-15 Targeting PTSD and Stress-Induced Anxiety Disorders
July 7, 2024
Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety
June 25, 2024
Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia
June 6, 2024
Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
June 4, 2024
Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety
June 3, 2024
Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention
May 20, 2024
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
April 22, 2024
Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic
April 9, 2024
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
March 19, 2024
Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
March 17, 2024
Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
February 27, 2024
Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery
February 13, 2024
Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
January 31, 2024
Silo Pharma Announces Positive Results in Alzheimer’s Disease Study
January 23, 2024
Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD
January 3, 2024
Decks in 2024
- Investor Presentation (September 2024)
Investor deck · 18 slides · Sep 10, 2024